Previous 10 | Next 10 |
Applied DNA Sciences, Inc. (APDN) Q3 2019 Earnings Conference Call August 13, 2019, 04:30 PM ET Company Participants Clay Shorrock - General Counsel Beth Jantzen - CFO James Hayward - President, CEO and Chairman Conference Call Participants Andrew Lieber - AGP/Alliance Glob...
Applied DNA Sciences (NASDAQ: APDN ): Q3 GAAP EPS of -$0.04 misses by $0.05 . More news on: Applied DNA Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Company to Hold Conference Call and Webcast Today, Tuesday, August 13, 2019 at 4:30 PM EST. Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), announced consolidated financial results for the fiscal 2019 third quarter ended June 30, 2019. “...
LineaRx Positioned to Benefit from Increasing Demand for Nucleic-Acid Dependent Therapies; Potential to Make Redirected Cell Therapies, such as CAR T, Faster, Safer, More Effective and with Lower Design and Manufacturing Costs LineaRx, Inc. (“LineaRx”), a majority-owned s...
Platform for Functional Isolation of Invasive Circulating Tumor Cells Empowers Three LineaRx Product Categories: Diagnostics, Prognostics and Therapeutics; Creates Integrated Product and Service Offering LineaRx, Inc. (“LineaRx”), a wholly-owned subsidiary of Applied DNA...
Applied DNA products and services offer forensic, high-value differentiation for Schreiner MediPharm’s customers to secure supply chains Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”, the “Company”), a leader in PCR-based DNA manufactur...
Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today it plans to release financial results for its fiscal 2019 third quarter ended June 30, 2019 after market close on Tuesday, August 13, 2019. In conjunction with the release, the Company has scheduled a conference call at 4:30 p.m. Ea...
Amendments fortify the Agreement, allow revenue recognition, and strengthen the Applied DNA Balance Sheet Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based (Polymerase Chain Reaction) DNA manufacturing for pr...
Applied DNA Sciences ( APDN -3.5% ) has closed on $1.5M in gross proceeds in secured convertible notes with an accredited investor, Dillon Hill Capital. More news on: Applied DNA Sciences, Inc., Read more ...
Existing Notes Amended as Part of Plan to Strengthen Balance Sheet and Regain Nasdaq Listing Standards Compliance Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based (Polymerase Chain Reaction) DNA manufac...
News, Short Squeeze, Breakout and More Instantly...
Applied DNA Sciences Inc. Company Name:
APDN Stock Symbol:
NASDAQ Market:
Applied DNA Sciences Inc. Website:
2024-04-25 09:02:03 ET Applied Dna Sciences Inc (APDN) announced stock split at a ratio of 1-for-20 on 2024-04-25 ... Full story available on KlickAnalytics.com
STONY BROOK, NY / ACCESSWIRE / April 22, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-20 stock split of its common stock, to be effective as of 12:01 a.m. Eastern Time on Thursd...
- Project To Increase RNAP Manufacturing Capacity and Reduce Unit Costs of Goods - - Project Slated for Completion Coincident with Company's Planned Initiation of GMP Manufacturing for Linea ™ DNA IVT Templates - STONY BROOK, NY and JUPITER, FL / ACCESSWIRE / March 18, 2024 /...